European Society for Medical Oncology (ESMO) shared a post on LinkedIn:
“CAR-T cell therapies have been highly successful for treating B cell malignancies and have also recently shown potential for the treatment of solid tumours.
However, two major hurdles have slowed their development and widespread use: the toxicity/efficacy balance and logistic aspects linked to a complex manufacturing process.
Read the opinion by Philippe Cassier in the ESMO Daily Reporter.”
More posts featuring ESMO.